Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price hoisted by equities researchers at JPMorgan Chase & Co. from $276.00 to $300.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 46.88% from the company’s current price.

A number of other research analysts also recently commented on JAZZ. Deutsche Bank Aktiengesellschaft increased their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Piper Sandler boosted their price target on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen upped their price target on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Barclays lifted their price objective on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $292.05.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $2.53 during trading hours on Wednesday, hitting $204.25. The stock had a trading volume of 567,279 shares, compared to its average volume of 928,825. Jazz Pharmaceuticals has a one year low of $128.80 and a one year high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. The stock’s 50-day moving average price is $234.46 and its two-hundred day moving average price is $215.52. The stock has a market capitalization of $13.26 billion, a price-to-earnings ratio of 14.09, a PEG ratio of 0.26 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. Jazz Pharmaceuticals’s quarterly revenue was up 15.5% on a year-over-year basis. During the same period in the previous year, the company posted ($8.25) earnings per share. Equities analysts forecast that Jazz Pharmaceuticals will post 10.97 EPS for the current year.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the sale, the director owned 345,875 shares in the company, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the sale, the executive vice president owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This represents a 2.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,121 shares of company stock worth $24,855,802 in the last 90 days. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. USA Financial Formulas purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $32,000. Ameritas Advisory Services LLC purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $47,000. Westpac Banking Corp bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at about $51,000. Finally, Root Financial Partners LLC grew its holdings in Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 89 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.